Illumina, Inc. South Africa India California

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

highlighting how sequencing can aid the management of endemic diseases, including drug-resistant tuberculosis, an ongoing public health crisis. Genomics has recently been leveraged to detect the introduction of dengue virus type 3 genotypes to Brazil, which has important public health implications, and recent studies cite pathogen genomic sequencing as a critical tool for managing outbreaks such as Marburg virus, Ebola virus, and mpox, as well as part of a "One Health" approach to managing antimicrobial resistance.

"In an age where technology plays a crucial role in surveillance and diagnostics during pandemics, ensuring equitable access to these tools is not just a matter of fairness but a matter of global public health security," said Toni Whistler, US Centers for Disease Control detailee to The Global Fund. "The ability to monitor and diagnose diseases swiftly and accurately, without leaving vulnerable populations behind, is fundamental to our collective preparedness in the face of global health crises. The equitable access program developed and operationalized by Illumina will allow many low- and middle-income nations to participate in the future of genomics across public health and preparedness."

Learn more about the Global Health Access Initiative.

About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023 we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts

Investors:
Salli Schwartz
858-291-6421
[e-mail]

Media:
David McAlpine
347-327-1336
[e-mail]

View original content:https://www.prnewswire.co.uk/news-releases/illumina-launches-global-health-access-initiative-to-support-acceleration-of-pathogen-sequencing-in-low--and-middle-income-countries-301985470.html